First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

Oncologist

Volumn 17, Issue 1, 2012, Pages 15-25

  Díaz Rubio, Eduardo ^a   Gómez España, Auxiliadora ^b   Massutí, Bartomeu ^c   Sastre, Javier ^a   Abad, Albert ^d   Valladares, Manuel ^e   Rivera, Fernando ^f   Safont, Maria J ^g   de Prado, Purificación Martínez ^h   Gallén, Manuel ⁱ   González, Encarnación ^j   Marcuello, Eugenio ^k   Benavides, Manuel ^l   Fernández Martos, Carlos ^m   Losa, Ferrán ⁿ   Escudero, Pilar ^o   Arrivi, Antonio ^p   Cervantes, Andrés ^q   Dueñas, Rosario ^r   López Ladrón, Amelia ^s   Lacasta, Adelaida ^t   Llanos, Marta ^u   Tabernero, Jose M ^v   Antón, Antonio ^w   Aranda, Enrique ^b   more..

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF A CORUÑA   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^l HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^m INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁿ HOSPITAL GENERAL DE CATALUNYA   (Spain)

^o HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^p HOSPITAL SON LLÀTZER   (Spain)

^q UNIVERSITY OF VALENCIA   (Spain)

^r Servicio Andaluz de Salud   (Spain)

^s HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^t HOSPITAL DONOSTIA   (Spain)

^u HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^v HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^w HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

more..

Author keywords

5 FU; Bevacizumab; Capecitabine; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84856304557     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0249     Document Type: Article

References (29)

1. Díaz-Rubio E, Tabernero J, Gómez-España A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007;25: 4224-4230.
2. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-4223.
3. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-2012.
4. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26: 3523-3529.
5. Martoni AA, Pinto C, Di Fabio F et al. Capecitabine plus oxaliplatin (XELOX) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (PVI-FOX) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006;42: 3161-3168.
6. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J Clin Oncol 2008;26:5910-5917.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
8. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987-989.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
10. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019.
11. Giantonio BJ, Catalano PJ, Meropol NJ et al.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
12. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
13. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
14. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BriTE). J Clin Oncol 2008;26:5326-5334.
15. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. The Oncologist 2009;14:862-870.
16. Kozloff MF, Berlin J, Flynn PJ et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. Oncology 2010;78:329-339.
17. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009;20:1842-1847.
18. Maughan TS, James RD, Kerr DJ et al.; Medical Research Council Colorectal Cancer Group. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 2003;361: 457-464.
19. Labianca R, Sobrero A, Isa L et al.; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: A randomised 'GISCAD' trial. Ann Oncol 2011;22: 1236-1242.
20. Grothey A, Hart L, Rowland K et al. Intermittent oxaliplatin (oxali) administration and time-totreatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial [abstract 4010]. J Clin Oncol 2008; 26(15 suppl):180.
21. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.
22. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27:5727-5733.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
24. Adams R, Wilson R, Seymour M et al. Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: A randomized non-inferiority trial (MRC COIN) [abstract 15LBA]. Eur J Cancer 2009(suppl 7):259.
25. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group [abstract 365]. J Clin Oncol 2011;29(suppl 4):10.
26. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
27. Van Cutsem E, Khöne CH, Hiltre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417.
28. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27: 663-671.
29. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697-4705.